Results 81 to 90 of about 14,945 (175)

Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry

open access: yesRMD Open
Objective Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated ...
Tilmann Kallinich   +19 more
doaj   +1 more source

CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

open access: yesПедиатрическая фармакология, 2013
The article presents a case of successful use of therapeutic monoclonal antibodies to interleukin 1 (canakinumab) at severe systemic juvenile idiopathic arthritis.
R. V. Denisova   +2 more
doaj   +1 more source

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease [PDF]

open access: yes, 2017
Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.
A, Abbate   +2121 more
core   +7 more sources

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

open access: yesJournal of the American Geriatrics Society, EarlyView.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui   +11 more
wiley   +1 more source

What makes gouty inflammation so variable? [PDF]

open access: yes, 2017
Acute gout arthritis flares contribute dominantly to gout-specific impaired health-related quality of life, representing a progressively increasing public health problem.
Terkeltaub, Robert
core   +2 more sources

Adult‐Onset Still's Disease(AOSD) With Features Suggestive of Macrophages Activation Syndrome in Young Female: A Rare Case Report From Nepal

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Adult‐onset Still's disease (AOSD) is a rare, multisystem autoinflammatory disorder characterized by a classic triad of fever, evanescent rash, and arthritis with diagnostic challenges. We present a case of a previously healthy 22‐year‐old Nepalese female presented with a 1.5‐month history of progressive bilateral lower limb edema and a 13‐day
Sushil Silwal   +3 more
wiley   +1 more source

Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database

open access: yesArthritis Research & Therapy
Background Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Receptor ...
Isabelle Koné-Paut   +7 more
doaj   +1 more source

Clonal Haematopoiesis in Type 2 Diabetes: A Review of Mechanistic Links With Inflammation and Cardiovascular Disease

open access: yesDiabetes/Metabolism Research and Reviews, Volume 42, Issue 2, February 2026.
ABSTRACT Clonal haematopoiesis (CH) has been recognized as an important interface between chronic inflammation, metabolic dysfunction, and the heightened cardiovascular risk observed in type 2 diabetes (T2D). CH arises from somatic mutations that give haematopoietic stem cells a competitive advantage and drive the expansion of pro‐inflammatory myeloid ...
Ludovica Migliozzi   +3 more
wiley   +1 more source

Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis [PDF]

open access: yes, 2012
Objective Systemic juvenile idiopathic arthritis (JIA) is characterized by fevers, rash, and arthritis, for which interleukin‐1 (IL‐1) and IL‐6 inhibitors appear to be effective treatments.
Carol A. Wallace   +19 more
core   +1 more source

Single‐Chain Anti‐IL‐1β Antibody Carried by Outer Membrane Vesicles of Bacteroides fragilis Alleviates Tubular Inflammation in Chronic Kidney Disease

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 2, February 2026.
Engineered Bacteroides fragilis outer membrane vesicles carrying anti‐IL‐1β scFv and kidney‐targeting peptides alleviate renal inflammation and injury in CKD mouse models via precise delivery and NF‐κB inhibition. ABSTRACT Microinflammation is a key driver of chronic kidney disease (CKD) progression, with interleukin‐1β (IL‐1β) playing a pivotal role ...
Liang Li   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy